Argininosuccinic aciduria: clinical and biochemical phenotype findings in Malaysian children.
- Author:
Chen, Bee Chin
;
Ngu, Lock Hock
;
Zabedah, Md Yunus
- Publication Type:Journal Article
- MeSH:
Age of Onset;
Amino Acids/analysis;
Argininosuccinic Acid/blood;
Argininosuccinic Acid/urine;
Argininosuccinic Aciduria/*diagnosis;
Argininosuccinic Aciduria/*metabolism;
Argininosuccinic Aciduria/*physiopathology;
Malaysia;
Phenotype
- From:The Malaysian Journal of Pathology
2010;32(2):87-95
- CountryMalaysia
- Language:English
-
Abstract:
Argininosuccinic aciduria is an inborn error of the urea cycle caused by deficiency of argininosuccinate lyase (ASL). ASL-deficient patients present with progressive intoxication due to accumulation of ammonia in the body. Early diagnosis and treatment of hyperammonemia are necessary to improve survival and prevent long-term handicap. Two clinical phenotypes have been recognized--neonatal acute and milder late-onset form. We investigated patients with hyperammonemia by a stepwise approach in which quantitative amino acids analysis was the core diagnostic procedure. Here, we describe the clinical phenotypes and biochemical characteristics in diagnosing this group of patients. We have identified 13 patients with argininosuccinic aciduria from 2003 till 2009. Ten patients who presented with acute neonatal hyperammonemic encephalopathy had markedly elevated blood ammonia (> 430 micromol/L) within the first few days of life. Three patients with late-onset disease had more subtle clinical presentations and they developed hyperammonemia only during the acute catabolic state at two to twelve months of age. Their blood ammonia was mild to moderately elevated (> 75-265 micromol/L). The diagnosis was confirmed by detection of excessive levels of argininosuccinate in the urine and/or plasma. They also have moderately increased levels of citrulline and, low levels of arginine and ornithine in their plasma. Two patients succumbed to the disease. To date, eleven patients remained well on a dietary protein restriction, oral ammonia scavenging drugs and arginine supplementation. The majority of them have a reasonable good neurological outcome.
